loading
전일 마감가:
$2.11
열려 있는:
$2.15
하루 거래량:
51,586
Relative Volume:
0.32
시가총액:
$78.77M
수익:
$1.79M
순이익/손실:
$-70.90M
주가수익비율:
-0.1452
EPS:
-15.54
순현금흐름:
$-34.95M
1주 성능:
+12.67%
1개월 성능:
-28.24%
6개월 성능:
-35.80%
1년 성능:
-46.03%
1일 변동 폭
Value
$2.15
$2.2502
1주일 범위
Value
$1.97
$2.2502
52주 변동 폭
Value
$1.5201
$16.94

센티 바이오사이언시스 Stock (SNTI) Company Profile

Name
명칭
Senti Biosciences Inc
Name
전화
(650) 382-3281
Name
주소
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Name
직원
48
Name
트위터
Name
다음 수익 날짜
2024-08-16
Name
최신 SEC 제출 서류
Name
SNTI's Discussions on Twitter

SNTI을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SNTI
Senti Biosciences Inc
2.23 78.77M 1.79M -70.90M -34.95M -15.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
455.19 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
544.95 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.27 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
559.17 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.94 28.51B 3.81B -644.79M -669.77M -6.24

센티 바이오사이언시스 Stock (SNTI) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-06 개시 Laidlaw Buy
2022-10-07 개시 Morgan Stanley Equal-Weight

센티 바이오사이언시스 주식(SNTI)의 최신 뉴스

pulisher
Jun 18, 2025

Senti Biosciences Inc (SNTI) Stock: Uncovering 52-Week Market Trends - investchronicle.com

Jun 18, 2025
pulisher
Jun 18, 2025

Senti Bio Receives US FDA Orphan Drug Designation for Potential Blood Cancer Treatment - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Senti Biosciences, Inc. Reports Progress in Phase 1 Trial of SENTI-202 for Acute Myeloid Leukemia, Receives Orphan Drug Designation - Nasdaq

Jun 18, 2025
pulisher
Jun 18, 2025

FDA grants orphan drug designation to Senti Bio’s AML treatment - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Backs Senti Bio Revolutionary Cancer Drug as 60% of AML Patients Face Critical Outcomes - Stock Titan

Jun 18, 2025
pulisher
Jun 13, 2025

Senti Biosciences (NASDAQ:SNTI) Receives Buy Rating from Chardan Capital - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Senti Biosciences (SNTI) Rating and Price Target Updated by Chardan Capital | SNTI Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 09, 2025

Senti Biosciences Announces New Employment Inducement Grants - The Manila Times

Jun 09, 2025
pulisher
Jun 09, 2025

Gene Circuit Pioneer Senti Bio Grants $310K in Stock Options to Expand Next-Gen Therapy Team - Stock Titan

Jun 09, 2025
pulisher
Jun 08, 2025

Laidlaw Initiates Coverage on Senti Biosciences (NASDAQ:SNTI) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Investors to Inquire about Securities Investigation - ACCESS Newswire

Jun 07, 2025
pulisher
Jun 07, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc.SNTI - WV News

Jun 07, 2025
pulisher
Jun 07, 2025

SNTI: Senti Biosciences Receives "Buy" Rating from Laidlaw & Co. | SNTI Stock News - GuruFocus

Jun 07, 2025
pulisher
Jun 06, 2025

Laidlaw & Co. Initiates Coverage of Senti Biosciences (SNTI) with Buy Recommendation - Nasdaq

Jun 06, 2025
pulisher
Jun 06, 2025

SNTI: Senti Biosciences Receives "Buy" Rating from Laidlaw & Co. - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC - The Manila Times

Jun 06, 2025
pulisher
Jun 06, 2025

Exclusive: Senti Bio Leaders Reveal Next-Gen Cell Therapy Vision in Chardan Fireside Discussion - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

Senti Bio (SNTI) Receives Buy Rating from Laidlaw with $5 Target - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Senti Bio (SNTI) Receives Buy Rating from Laidlaw with $5 Target | SNTI Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Laidlaw initiates coverage on Senti Biosciences stock with buy rating By Investing.com - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

Laidlaw initiates coverage on Senti Biosciences stock with buy rating - Investing.com

Jun 06, 2025
pulisher
Jun 02, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amerant Bancorp Inc. - GlobeNewswire Inc.

Jun 02, 2025
pulisher
Jun 02, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti ... - Bluefield Daily Telegraph

Jun 02, 2025
pulisher
May 30, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc - ACCESS Newswire

May 30, 2025
pulisher
May 30, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

May 30, 2025
pulisher
May 29, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation Into Senti Biosciences Inc - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise - insights.citeline.com

May 29, 2025
pulisher
May 27, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

May 27, 2025
pulisher
May 26, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

May 26, 2025
pulisher
May 26, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc.GMED - PR Newswire

May 26, 2025
pulisher
May 25, 2025

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 25, 2025
pulisher
May 23, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc - ACCESS Newswire

May 23, 2025
pulisher
May 23, 2025

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar - The Manila Times

May 23, 2025
pulisher
May 22, 2025

Senti Bio CEO Reveals Next-Gen Gene Circuit Platform: Live Webull Biotech Investment Presentation Coming May 29 - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Senti Bio (SNTI) Secures Additional Funding for SENTI-202 Develo - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Senti Bio (SNTI) Secures Additional Funding for SENTI-202 Development | SNTI Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Senti Biosciences Receives Additional $1 Million from CIRM to Support Clinical Development of SENTI-202 Cell Therapy - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202 - Yahoo Finance

May 22, 2025
pulisher
May 20, 2025

SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm - marketscreener.com

May 20, 2025
pulisher
May 16, 2025

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 16, 2025
pulisher
May 09, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc. - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

Senti Biosciences advances AML treatment with SENTI-202 trial By Investing.com - Investing.com Nigeria

May 09, 2025
pulisher
May 08, 2025

Senti Biosciences advances AML treatment with SENTI-202 trial - Investing.com

May 08, 2025
pulisher
May 08, 2025

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 - The Manila Times

May 08, 2025
pulisher
May 07, 2025

Renaissance Technologies LLC Makes New $181,000 Investment in Senti Biosciences, Inc. (NASDAQ:SNTI) - Defense World

May 07, 2025
pulisher
May 07, 2025

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development - The Manila Times

May 07, 2025
pulisher
May 06, 2025

Senti Biosciences Reports Positive Phase 1 Results for SENTI-202 in Acute Myeloid Leukemia Treatment - Nasdaq

May 06, 2025
pulisher
May 06, 2025

Senti Bio Phase 1 Trial Shows 57% Complete Remission Rate in AML Treatment | SNTI Stock News - Stock Titan

May 06, 2025
pulisher
May 05, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti ... - Bluefield Daily Telegraph

May 05, 2025
pulisher
May 05, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTI - FinancialContent

May 05, 2025

센티 바이오사이언시스 (SNTI) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

센티 바이오사이언시스 주식 (SNTI) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Lu Timothy K
CEO
Feb 06 '25
Sale
4.36
545
2,376
82,082
Rajangam Kanya
Pres. & Chief Med. & Dev. Off.
Feb 04 '25
Sale
4.07
1,297
5,279
8,803
Rajangam Kanya
Pres. & Chief Med. & Dev. Off.
Feb 06 '25
Sale
4.37
182
795
8,621
$20.95
price up icon 1.46%
$36.04
price up icon 0.14%
$21.25
price down icon 0.39%
$98.93
price down icon 1.52%
$108.80
price up icon 2.21%
biotechnology ONC
$244.22
price up icon 0.68%
자본화:     |  볼륨(24시간):